불면증 약물 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 의약품별, 치료별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Insomnia Pharmacological Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug, By Treatment, By Distribution Channel, By Region and Competition, 2020-2030F
불면증 약리학 치료 세계 시장 규모는 2024년 38억 1,000만 달러로 평가되었고, 2030년까지 연평균 5.73%의 연평균 복합 성장률(CAGR)을 반영하여 53억 3,000만 달러에 달할 것으로 예상됩니다.
이 시장은 전 세계적으로 수면장애의 유병률이 증가함에 따라 괄목할 만한 성장세를 보이고 있습니다. 스트레스 증가, 생활습관 변화, 고령화 등의 요인으로 인해 불면증 약물 치료에 대한 수요가 증가하고 있습니다. 이 시장에는 벤조디아제핀계 최면제, 비벤조디아제핀계 최면제, 멜라토닌 수용체 작용제, 올레신 수용체 길항제 등 다양한 처방약과 일반의약품이 포함됩니다. 제약사들은 기존 수면유도제 관련 의존성 및 부작용 문제를 해결하기 위해 보다 안전하고 효과적인 약물을 개발하는 데 주력하고 있습니다. 새로운 치료법에 대한 규제 당국의 승인과 약물 제형의 혁신은 시장 성장을 더욱 촉진하여 환자들에게 더 나은 효능과 부작용 감소를 제공합니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
38억 1,000만 달러 |
| 시장 규모 : 2030년 |
53억 3,000만 달러 |
| CAGR : 2025-2030년 |
5.73% |
| 급성장 부문 |
OTC 수면 보조제 |
| 최대 시장 |
북미 |
치료되지 않은 불면증으로 인한 장기적인 건강 위험에 대한 인식이 높아지면서 불면증 진단 건수가 증가하고 처방에 기반한 솔루션에 대한 수요가 증가하고 있습니다. 서방형 제제 및 이중 작용 제제의 혁신으로 밤새도록 지속적인 수면을 보장하여 치료 결과를 개선하고 있습니다. 또한, 개인 맞춤형 의료와 바이오마커 기반 치료 증가 추세는 불면증 치료 환경을 재구성하고 있습니다. 멜라토닌을 주성분으로 하는 수면 보조제와 같은 자연적이고 중독성이 없는 솔루션을 찾는 소비자 수요는 신제품 개발의 원동력이 되고 있습니다. 설하정이나 경피 패치를 포함한 약물 전달 시스템의 발전은 다양한 환자들의 요구를 충족시킬 수 있는 치료 옵션을 넓혀주고 있습니다. 제약회사와 연구기관의 전략적 제휴는 비진정성 표적 치료제의 개발을 가속화하고 있으며, 이는 시장 확대를 더욱 촉진하고 있습니다.
주요 시장 성장 촉진요인
불면증 유병률 증가
주요 시장 이슈
장기 사용에 대한 우려
주요 시장 동향
의약품의 발전
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 불면증 약물 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 의약품별(OTC 의약품, OTC 수면 보조제, OTC 수면 보충제, 처방약)
- 치료별(시판 수면제, 처방전 수면제)
- 유통 채널별(드럭스토어, E-Commerce, 병원 약국, 소매 약국)
- 기업별(2024년)
- 지역별
- 시장 맵
제6장 북미의 불면증 약물 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 불면증 약물 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 불면증 약물 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 불면증 약물 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 불면증 약물 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
- 인수합병(M&A)(있는 경우)
- 제품 발매(있는 경우)
- 최근 동향
제13장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제14장 경쟁 구도
- Merck & Co Inc
- Ebb Therapeutics Inc/US
- Pfizer Inc
- Sanofi SA
- Takeda Pharmaceutical Co Ltd
- Paratek Pharmaceuticals Inc
- Electromedical Products International Inc
- Meda Pharmaceuticals Inc
- Purdue Pharma LP
- Pernix Therapeutics Holdings Inc
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
The global insomnia pharmacological treatment market was valued at USD 3.81 billion in 2024 and is projected to reach USD 5.33 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.73%. The market is experiencing significant growth, driven by the rising prevalence of sleep disorders across the globe. Factors such as increasing stress, lifestyle changes, and the growing aging population are intensifying the demand for pharmacological treatments for insomnia. This market includes a broad spectrum of prescription and over-the-counter drugs, including benzodiazepines, non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists. Pharmaceutical companies are focusing on developing safer, more effective medications to address issues related to dependency and adverse effects associated with traditional sleep aids. Regulatory approvals for novel treatments and innovations in drug formulations are further stimulating market growth, providing patients with improved efficacy and reduced side effects.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 3.81 Billion |
| Market Size 2030 | USD 5.33 Billion |
| CAGR 2025-2030 | 5.73% |
| Fastest Growing Segment | OTC Sleep Supplements |
| Largest Market | North America |
Heightened awareness about the long-term health risks of untreated insomnia is leading to more diagnoses and a growing demand for prescription-based solutions. Innovations in extended-release and dual-action formulations are improving treatment outcomes by ensuring sustained sleep throughout the night. Additionally, the growing trend toward personalized medicine and biomarker-based therapies is reshaping the landscape of insomnia treatment. Consumer demand for natural, non-habit-forming solutions, such as melatonin-based sleep aids, is driving new product development. Advances in drug delivery systems, including sublingual tablets and transdermal patches, are expanding treatment options to meet diverse patient needs. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the development of non-sedative, targeted therapies, further supporting market expansion.
Key Market Drivers
Increasing Prevalence of Insomnia:
In today's fast-paced, digitally connected world, achieving quality sleep has become more challenging. Insomnia, characterized by persistent difficulties in falling asleep, staying asleep, or achieving restorative sleep, is on the rise. This increase in insomnia cases significantly contributes to the growth of the global pharmacological insomnia treatment market. Work-related stress, personal pressures, and constant exposure to screens have led to a substantial rise in sleep disturbances. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2020, approximately 14.5% of U.S. adults reported trouble falling asleep, and 17.8% had difficulty staying asleep regularly, underscoring the growing demand for treatment solutions.
Key Market Challenges
Concerns Over Long-Term Use:
One of the major challenges facing the global insomnia pharmacological treatment market is the concerns associated with the long-term use of medications. Prescription drugs used for insomnia treatment, such as benzodiazepines, non-benzodiazepine hypnotics, and certain antidepressants, can pose significant risks when used over extended periods. Prolonged use can lead to tolerance, dependency, withdrawal symptoms, and cognitive impairments. Over time, patients may require higher doses to achieve the same therapeutic effects, potentially leading to misuse or addiction. Furthermore, the risk of rebound insomnia when discontinuing these medications can worsen sleep disturbances. Long-term use of sedative-hypnotic medications has also been linked to adverse health effects, including cognitive decline and an increased risk of falls, particularly among elderly patients. Regulatory agencies like the U.S. FDA and the European Medicines Agency (EMA) have raised concerns about these risks, leading to stricter guidelines and closer scrutiny of chronic insomnia management.
As awareness of these issues grows, healthcare providers are exploring alternative treatments, such as cognitive behavioral therapy for insomnia (CBT-I) and lifestyle interventions, before resorting to long-term pharmacological solutions. Pharmaceutical companies face the challenge of developing new insomnia treatments that minimize dependency risks and cognitive side effects, while maintaining their effectiveness. These concerns are influencing prescription patterns, regulatory policies, and patient preferences, thereby shaping the future trajectory of the insomnia pharmacological treatment market.
Key Market Trends
Advancements in Pharmaceuticals:
The field of sleep disorders, particularly insomnia, has long been elusive, but recent advancements in pharmaceuticals are providing new insights into effective treatment options. These innovations are transforming insomnia management, offering hope and relief to individuals who have long struggled with sleep disturbances. Modern research has led to the development of new insomnia medications that are not only more effective but also safer, with fewer adverse side effects, making them more attractive to both patients and healthcare providers.
In-depth understanding of sleep regulation mechanisms has enabled the creation of targeted therapies that address specific aspects of insomnia, such as difficulties falling or staying asleep, providing more personalized and effective treatment options. Newer drugs are reducing the risks of dependency that plagued earlier sleep medications like benzodiazepines. Furthermore, some newer insomnia treatments offer longer-lasting effects, supporting sustained and restorative sleep throughout the night, improving the overall sleep experience.
Another key area of focus is minimizing next-day impairments, such as drowsiness and cognitive deficits, allowing individuals to maintain their daily activities. Advanced insomnia medications are also addressing comorbidities such as anxiety, depression, or chronic pain, offering a holistic approach to treatment.
Key Market Players:
- Merck & Co Inc.
- Ebb Therapeutics Inc. (USA)
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- Paratek Pharmaceuticals Inc.
- Electromedical Products International Inc.
- Meda Pharmaceuticals Inc.
- Purdue Pharma LP
- Pernix Therapeutics Holdings Inc.
Report Scope: This report segments the global insomnia pharmacological treatment market into various categories, including industry trends and detailed analysis of the following areas:
By Drug:
- Over-the-Counter (OTC) Drugs
- OTC Sleep Aids
- OTC Sleep Supplements
- Prescription Drugs
By Treatment:
- Over-the-Counter Sleep Aids
- Prescription Sleep Aids
By Distribution Channel:
- Drug Stores
- E-Commerce
- Hospital Pharmacies
- Retail Pharmacies
By Region:
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Italy, Spain)
- Asia-Pacific (China, Japan, India, Australia, South Korea)
- South America (Brazil, Argentina, Colombia)
- Middle East & Africa (South Africa, Saudi Arabia, UAE)
Competitive Landscape: In-depth analysis of leading companies in the global insomnia pharmacological treatment market.
Available Customizations: TechSci Research offers customized reports based on specific company needs. Customization options include:
- Company Information: Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Insomnia Pharmacological Treatment Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Drug (OTC Drugs, OTC Sleep Aids, OTC Sleep Supplements, Prescription Drugs)
- 5.2.2. By Treatment (Over-the-Counter Sleep Aids, Prescription Sleep Aids)
- 5.2.3. By Distribution Channel (Drug Stores, E-Commerce, Hospital Pharmacies, Retail Pharmacies)
- 5.2.4. By Company (2024)
- 5.2.5. By Region
- 5.3. Market Map
6. North America Insomnia Pharmacological Treatment Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Drug
- 6.2.2. By Treatment
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Insomnia Pharmacological Treatment Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drug
- 6.3.1.2.2. By Treatment
- 6.3.1.2.3. By Distribution Channel
- 6.3.2. Mexico Insomnia Pharmacological Treatment Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drug
- 6.3.2.2.2. By Treatment
- 6.3.2.2.3. By Distribution Channel
- 6.3.3. Canada Insomnia Pharmacological Treatment Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drug
- 6.3.3.2.2. By Treatment
- 6.3.3.2.3. By Distribution Channel
7. Europe Insomnia Pharmacological Treatment Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Drug
- 7.2.2. By Treatment
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Insomnia Pharmacological Treatment Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug
- 7.3.1.2.2. By Treatment
- 7.3.1.2.3. By Distribution Channel
- 7.3.2. Germany Insomnia Pharmacological Treatment Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug
- 7.3.2.2.2. By Treatment
- 7.3.2.2.3. By Distribution Channel
- 7.3.3. United Kingdom Insomnia Pharmacological Treatment Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug
- 7.3.3.2.2. By Treatment
- 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Insomnia Pharmacological Treatment Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drug
- 7.3.4.2.2. By Treatment
- 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Insomnia Pharmacological Treatment Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drug
- 7.3.5.2.2. By Treatment
- 7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Insomnia Pharmacological Treatment Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Drug
- 8.2.2. By Treatment
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Insomnia Pharmacological Treatment Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug
- 8.3.1.2.2. By Treatment
- 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Insomnia Pharmacological Treatment Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug
- 8.3.2.2.2. By Treatment
- 8.3.2.2.3. By Distribution Channel
- 8.3.3. South Korea Insomnia Pharmacological Treatment Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug
- 8.3.3.2.2. By Treatment
- 8.3.3.2.3. By Distribution Channel
- 8.3.4. Japan Insomnia Pharmacological Treatment Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug
- 8.3.4.2.2. By Treatment
- 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Insomnia Pharmacological Treatment Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug
- 8.3.5.2.2. By Treatment
- 8.3.5.2.3. By Distribution Channel
9. South America Insomnia Pharmacological Treatment Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Drug
- 9.2.2. By Treatment
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Insomnia Pharmacological Treatment Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug
- 9.3.1.2.2. By Treatment
- 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Insomnia Pharmacological Treatment Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug
- 9.3.2.2.2. By Treatment
- 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Insomnia Pharmacological Treatment Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug
- 9.3.3.2.2. By Treatment
- 9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Insomnia Pharmacological Treatment Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Drug
- 10.2.2. By Treatment
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Insomnia Pharmacological Treatment Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug
- 10.3.1.2.2. By Treatment
- 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Insomnia Pharmacological Treatment Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug
- 10.3.2.2.2. By Treatment
- 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Insomnia Pharmacological Treatment Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug
- 10.3.3.2.2. By Treatment
- 10.3.3.2.3. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Porters Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. Merck & Co Inc
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. Ebb Therapeutics Inc/US
- 14.3. Pfizer Inc
- 14.4. Sanofi SA
- 14.5. Takeda Pharmaceutical Co Ltd
- 14.6. Paratek Pharmaceuticals Inc
- 14.7. Electromedical Products International Inc
- 14.8. Meda Pharmaceuticals Inc
- 14.9. Purdue Pharma LP
- 14.10. Pernix Therapeutics Holdings Inc
15. Strategic Recommendations
16. About Us & Disclaimer
